NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. trades on Nasdaq under the ticker BRPA following its business combination with Big Rock Partners Acquisition Corp, a blank-check company sponsored by Big Rock Partners LLC that completed its initial public offering in 2019. The SPAC targeted the healthcare and life sciences sector, and the de-SPAC transaction with NRX closed in late 2020, bringing the clinical-stage biopharmaceutical company into the public markets. NRX focuses on developing treatments for life-threatening conditions, including its lead candidate aviptadil. The company filed an 8-K with the Securities and Exchange Commission on September 1, 2023, reflecting ongoing post-merger public company activity. Sign up at SpacDesk for complete filing history, deal timelines, and real-time SPAC analytics on BRPA and hundreds of other transactions.